MedTrace Logo

A Study of VV-14305 for the Treatment of Thyroid Eye Disease

NCT07404111 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2026-08-27

No results posted yet for this study

Summary

The goal of this study is to evaluate the safety, tolerability, and efficacy of KRIYA-586 (VV-14305) in treating thyroid eye disease (TED).

Conditions

  • Thyroid Eye Disease (TED)

Interventions

GENETIC

VV-14305

VV-14305 will be administered via peribulbar injection.

OTHER

Sham (No Treatment)

Sham solution such as Saline

Sponsors & Collaborators

  • Kriya Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2028-08-31
Completion
2029-08-31
FDA Drug
Yes

Countries

  • United States
  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07404111 on ClinicalTrials.gov